Analyst Price Targets — PRLD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 27, 2026 11:33 am | — | H.C. Wainwright | $8.00 | $4.70 | TheFly | Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright |
| September 10, 2024 6:43 am | Robert Burns | H.C. Wainwright | $5.00 | $5.17 | StreetInsider | H.C. Wainwright Reiterates Neutral Rating on Prelude Therapeutics (PRLD) |
| June 20, 2024 5:33 am | Peter Lawson | Barclays | $3.00 | $3.87 | TheFly | Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays |
| March 13, 2024 2:51 am | Reni Benjamin | JMP Securities | $7.00 | $4.62 | StreetInsider | JMP Securities Starts Prelude Therapeutics (PRLD) at Market Outperform, 'Precision Targeting of SMARCA Drives Cell Kill' |
| November 17, 2022 6:12 am | — | H.C. Wainwright | $15.00 | $7.70 | Benzinga | HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15 |
| November 15, 2022 8:41 am | — | Morgan Stanley | $10.00 | $8.10 | Benzinga | Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $10 |
Latest News for PRLD
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Bioasis Technologies (OTCMKTS:BIOAF - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. Institutional and Insider Ownership 79.7% of Prelude Therapeutics
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRLD.
U.S. House Trading
No House trades found for PRLD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.